The world’s first malaria vaccine approved for use in children in Africa
The world’s first malaria vaccine has been approved for general use by children in sub-Saharan Africa, as well as other regions, with moderate to high rates of the disease. “It’s a historic moment. The long-awaited malaria vaccine for children is a breakthrough in science, child health and malaria control, said Tedros Adhanom Gabrias, director general of the World Health Organization.
Malaria is responsible for more than 400,000 deaths each year from parasites spread by infected mosquito bites, most of them in young children in sub-Saharan Africa. It is mainly used by people to reduce the spread of pesticide traps and drug treatments.
The vaccine, called RTS, S or Mosquirix, contains a portion of the protein from the parasite from the hepatitis B virus, which is from the hepatitis B virus, which helps immune cells recognize the substance. Given as four doses from 5 months of age, it has been in development for about 40 years.
The WHO said yesterday that the use of vaccines reduces the incidence of serious or fatal malaria by 30%, even where bed nets are widely used. This effect is lower than that of vaccines against other diseases-for example, some Covid 19 vaccines have a 60 to 90% effect against severe disease.
Recent trials have also shown that families who have vaccinated their children continue to use bed nets and that the vaccine is cost-effective.
Approval the vaccine for general use “increases equality in access to malaria prevention, helps reach children who may not benefit from other interventions, such as bed nets,” for the development of malaria Says Nanthali Mugala at PATH, a global non-profit organization.